Clinical trials: Treatment naïve
Primary Biliary Cholangitis (PBC)
FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
The goal of this clinical trial is to learn if the drug Fenofibrate works to treat adults with a liver disease called Primary Biliary Cholangitis (PBC) who have not received previous treatment.
- Trial name
- NCT07296458
- Testing
- Fenofibrate, UDCA (Ursodeoxycholic acid)
- Where
- 2 sites in China
- Volunteers
- 132 people
- Sponsor
- Xijing Hospital of Digestive Diseases
HIV Infection
Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients
The purpose of this study is to obtain a preliminary assessment of the antiviral activity and tolerability of simplified Kaletra dual agent therapy as initial treatment for HIV infection, relative to a Kaletra three drug standard…
- Trial name
- KALEAD (NCT00234910)
- Testing
- Tenofovir DF, lopinavir/ritonavir with 2 Nucleoside RTIs
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Abbott
Macular Degeneration
Analysis of naïve Patients With Age-related Macular Degeneration Neovascular Type and Treated With Ranibizumab (Lucentis®) in Treat-and-extend at the CHU Brugmann.
Age-related macular degeneration (AMD) is a leading cause of blindness in people over 50 years old. Neovascular AMD, the most severe form and the most severe is characterized by the appearance, spread and growth of subretinal…
- Trial name
- NCT04988178
- Testing
- Data extraction from medical files
- Where
- Belgium
- Volunteers
- 34 people
- Sponsor
- Brugmann University Hospital
Chronic Hepatitis C
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
The purpose of this study is to estimate the rate of sustained virologic response (SVR) SVR12, where SVR12 is defined as HCV RNA < LOQ (detectable or undetectable) 12 weeks post-treatment in Genotype 1 \& Genotype 4 treatment…
- Trial name
- NCT01455090
- Testing
- BMS-650032, BMS-790052, BMS-791325
- Where
- 32 sites in United States, France and 1 more
- Volunteers
- 320 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
This phase II trial compares two treatment combinations: gemcitabine hydrochloride and nab-paclitaxel, or fluorouracil, leucovorin calcium, and liposomal irinotecan in older patients with pancreatic cancer that has spread to…
- Trial name
- NCT04233866
- Testing
- Fluorouracil, Gemcitabine, Gemcitabine Hydrochloride
- Where
- 760 sites in United States
- Volunteers
- 176 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
HIV
Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment
The purpose of this research study is to compare changes in triglyceride and other lipids (levels of fats found in the blood) from Baseline (Day 1) to Week 12 for darunavir/ritonavir 800/100 mg once daily versus…
- Trial name
- NCT00757783
- Testing
- ritonavir, darunavir, emtricitabine [FTC]/tenofovir [TDF]
- Where
- 15 sites in United States
- Volunteers
- 68 people
- Sponsor
- Tibotec, Inc
Follicular Lymphoma, Lymphoma
Odronextamab in Low Tumor Volume Advanced FL
The purpose of this study is to evaluate the safety and effectiveness of treating previously untreated Follicular Lymphoma (FL) with odronextamab.
- Trial name
- NCT07128641
- Testing
- Odronextamab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Gottfried von Keudell, MD PhD
Paroxysmal Nocturnal Hemoglobinuria
Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
This is a Phase 3b, single-arm, open-label, multicenter study to evaluate the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of eculizumab in adult participants with paraxysmal noturnal…
- Trial name
- Soliris (NCT05886244)
- Testing
- Eculizumab
- Where
- 7 sites in China
- Volunteers
- 25 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
HIV Infections
Durability of Nevirapine-Based Antiretroviral Regimen
Although nevirapine is used as an alternative to efavirenz for initial regimen in developed countries, nevirapine has still been a key antiretroviral drug in many resource-limited countries including Thailand due to its…
- Trial name
- NCT00703898
- Testing
- nevirapine
- Where
- Thailand
- Volunteers
- 140 people
- Sponsor
- Bamrasnaradura Infectious Diseases Institute
Chronic Hepatitis C, Chronic Hepatitis B
The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China
Subjects can be classified into two groups, Group 1 include non-cirrhotic patients, Group 2 include cirrhotic patients. All the patients will be received prophylactically TAF for 4 weeks before using SOF/VEL once daily for 12…
- Trial name
- BDTAF (NCT04997564)
- Testing
- Tenofovir Alafenamide 25 MG, Sofosbuvir / Velpatasvir
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking University First Hospital
Chronic Hepatitis C
Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C
Chronic hepatitis C virus (HCV) infection is common in dialysis patients. Interferon (IFN)-based treatment for chronic hepatitis C has been the mainstay therapy in immunocompetent patients.
- Trial name
- NCT00491244
- Testing
- Peginterferon alfa-2a and ribavirin, Peginterferon alfa-2a
- Where
- Taiwan
- Volunteers
- 377 people
- Sponsor
- National Taiwan University Hospital
Hepatitis C, Chronic
Dose Ranging of GSK2336805 in Combination Therapy
GSK2336805 is a novel hepatitis C virus (HCV) non-structural 5A (NS5A) inhibitor being developed for the treatment of chronic HCV infection.
- Trial name
- HAI115879 (NCT01648140)
- Testing
- GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a
- Where
- 34 sites in United States, Belgium and 4 more
- Volunteers
- 286 people
- Sponsor
- GlaxoSmithKline
HIV Infections
Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort
The purpose of this study is to determine whether the three generic nevirapine-based antiretroviral regimens are effective in the treatment of Acquired immune deficiency syndrome .
- Trial name
- NCT00618176
- Testing
- Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP), Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP), Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Peking Union Medical College
Premenopausal Breast Cancer
A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer
Hormone dynamics, pharmacokinetics, safety, and efficacy of TAP-144-SR(6M) will be evaluated against TAP-144-SR(3M) in postoperative and hormone therapy-naïve patients with premenopausal breast cancer
- Trial name
- NCT01546649
- Testing
- TAP-144-SR(6M), TAP-144-SR(3M)
- Where
- 15 sites in Japan
- Volunteers
- 167 people
- Sponsor
- Takeda
Metastatic Colorectal Cancer
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or…
- Trial name
- CodeBreaK 301 (NCT06252649)
- Testing
- FOLFIRI Regimen, Sotorasib, Panitumumab
- Where
- 291 sites in United States, Argentina and 33 more
- Volunteers
- 450 people
- Sponsor
- Amgen
Glioblastoma, Gliosarcoma
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
This phase II clinical trial studies how well ERC1671 plus Granulocyte-macrophage colony-stimulating factor (GM-CSF) plus Cyclophosphamide with Bevacizumab works compared to Placebo Injection plus Placebo Pill with Bevacizumab in…
- Trial name
- NCT01903330
- Testing
- ERC1671, GM-CSF, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 84 people
- Sponsor
- Epitopoietic Research Corporation
HIV-1 Infection
Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
This study will evaluate the safety, tolerability, antiretroviral activity, and pharmacokinetics of 3 doses of islatravir (MK-8591) in combination with doravirine (DOR) and lamivudine (3TC) administered to antiretroviral…
- Trial name
- NCT03272347
- Testing
- Islatravir, Doravirine, Lamivudine
- Where
- 26 sites in United States, Chile and 2 more
- Volunteers
- 123 people
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus
Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
The objective of this study is to observe and collect data on the usage, dosing, tolerability, and effectiveness of Kaletra (lopinavir/ritonavir) tablets in human immunodeficiency virus (HIV)-infected patients.
- Trial name
- NCT01097655
- Volunteers
- 3,049 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriatic Arthritis (PsA)
Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis
This study will investigate if the study medicine FT2109 can treat symptoms of active Psoriatic Arthritis (PsA). This study assesses the safety and efficacy of FT2109 in adult participants with active PsA who may or may not have…
- Trial name
- NCT07869134
- Testing
- FT2109 Dosing Regimen 1, FT2109 Dosing Regimen 2
- Volunteers
- 210 people
- Sponsor
- Forward Therapeutics
Acute Myeloid Leukaemia
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.
This is a Phase I/II clinical study to determine the maximum tolerated dose (MTD), and schedule, safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD2811 monotherapy or with combination agent(s) in…
- Trial name
- NCT03217838
- Testing
- AZD2811, Azacitidine, Venetoclax
- Where
- 11 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- AstraZeneca